Published in Br J Clin Pharmacol on May 06, 2008
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int (2009) 1.50
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int (2009) 1.39
The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab (2010) 0.99
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int (2009) 0.97
Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging (2009) 0.90
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int (2009) 0.87
The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J Clin Endocrinol Metab (2011) 0.86
Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Ther Adv Chronic Dis (2010) 0.80
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int (2011) 0.80
Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study. Eur J Clin Pharmacol (2014) 0.80
Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases. BMJ Open (2014) 0.78
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int (2008) 0.78
Survey of the utility of once-monthly bisphosphonate treatment for improvement of medication adherence in osteoporosis patients in Japan. J Bone Miner Metab (2014) 0.77
Once-monthly risedronate for postmenopausal osteoporosis. Int J Womens Health (2010) 0.76
Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study. J Bone Miner Metab (2011) 0.76
Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer (2017) 0.75
Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis. Clin Med Insights Arthritis Musculoskelet Disord (2012) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Modeling and variable selection in epidemiologic analysis. Am J Public Health (1989) 15.62
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Medication compliance and persistence: terminology and definitions. Value Health (2008) 7.58
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Assessment of fracture risk. Osteoporos Int (2004) 5.15
Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res (1992) 4.75
Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf (2006) 4.64
Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab (2001) 4.03
The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol (1995) 3.99
A checklist for medication compliance and persistence studies using retrospective databases. Value Health (2007) 3.64
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med (1991) 3.39
Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol (1995) 3.33
Biased selection of controls for case-control analyses of cohort studies. Biometrics (1984) 3.25
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int (2004) 2.88
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc (1999) 2.71
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone (2005) 2.66
Central nervous system active medications and risk for fractures in older women. Arch Intern Med (2003) 2.30
Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas (2004) 2.03
Early discontinuation of treatment for osteoporosis. Am J Med (2003) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med (2006) 1.90
Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med (2004) 1.86
Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol (2000) 1.74
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med (2007) 1.62
Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int (2006) 1.61
Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int (2007) 1.51
Cardiovascular diseases and future risk of hip fracture in women. Osteoporos Int (2007) 1.38
Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology (2006) 1.34
Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med (2004) 1.29
Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int (2006) 1.28
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int (2007) 1.21
The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin (2007) 1.17
Risk of hip fracture in disabled community-living older adults. J Am Geriatr Soc (2003) 1.08
Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf (2002) 1.07
A relative power table for nested matched case-control studies. Occup Environ Med (1999) 1.04
The role of socioeconomic status on hip fracture. Osteoporos Int (2006) 1.00
Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin (2007) 0.83
Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab (2007) 0.82
Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med (2012) 2.16
Varying conceptions of competence: an analysis of how health sciences educators define competence. Med Educ (2012) 1.94
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Determinants of the incidence of childhood asthma: a two-stage case-control study. Am J Epidemiol (2008) 1.78
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Delirium in older emergency department patients discharged home: effect on survival. J Am Geriatr Soc (2003) 1.61
Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care (2010) 1.57
A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. Drug Saf (2015) 1.45
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res (2006) 1.41
Mutations in NOTCH2 in families with Hajdu-Cheney syndrome. Hum Mutat (2011) 1.25
Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke (2008) 1.21
Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol (2006) 1.17
Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol (2002) 1.15
Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum. Drug Saf (2014) 1.14
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab (2005) 1.14
Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol (2007) 1.13
Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother (2005) 1.12
Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res (2011) 1.12
Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol (2009) 1.11
Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol (2007) 1.11
High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. Curr Osteoporos Rep (2013) 1.11
Ideal and actual involvement of community pharmacists in health promotion and prevention: a cross-sectional study in Quebec, Canada. BMC Public Health (2012) 1.09
A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. CMAJ (2010) 1.09
Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. J Cataract Refract Surg (2007) 1.08
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol (2005) 1.05
Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther (2002) 1.02
Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med (2009) 1.01
Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf (2007) 0.99
Physician-pharmacist collaborative care in dyslipidemia management: the perception of clinicians and patients. Res Social Adm Pharm (2010) 0.99
Recognizing osteoporosis and its consequences in Quebec (ROCQ): background, rationale, and methods of an anti-fracture patient health-management programme. Contemp Clin Trials (2007) 0.98
Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res (2006) 0.98
Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ (2005) 0.98
New measure of adherence adjusted for prescription patterns: the case of adults with asthma treated with inhaled corticosteroid monotherapy. Ann Pharmacother (2011) 0.97
Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther (2007) 0.97
Interferon-γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res (2011) 0.97
Adherence to antihypertensive agents improves risk reduction of end-stage renal disease. Kidney Int (2013) 0.96
Effect of maternal moderate to severe asthma on perinatal outcomes. Respir Med (2010) 0.93
The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing (2008) 0.93
Contemporary disease management in Quebec. Healthc Q (2008) 0.92
The depletion of susceptibles effect in the assessment of burden-of-illness: the example of age-related macular degeneration in the community-dwelling elderly population of Quebec. Can J Clin Pharmacol (2008) 0.92
Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol (2008) 0.91
Knowledge, attitudes and beliefs about chronic noncancer pain in primary care: a Canadian survey of physicians and pharmacists. Pain Res Manag (2014) 0.90
Suboptimal use of inhaled corticosteroids in children with persistent asthma: inadequate prescription, poor drug adherence, or both? Pharmacotherapy (2010) 0.90
Benzodiazepine use and quality of sleep in the community-dwelling elderly population. Aging Ment Health (2010) 0.89
Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial. Pituitary (2014) 0.89
Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. Drugs Aging (2015) 0.89
Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone (2005) 0.89
Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics (2012) 0.88
Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology (2012) 0.88
Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health (2009) 0.88
Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol (2010) 0.87
Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J (2008) 0.87
Health survey data on potentially inappropriate geriatric drug use. Ann Pharmacother (2002) 0.87
An Internet-Based Counseling Intervention With Email Reminders that Promotes Self-Care in Adults With Chronic Heart Failure: Randomized Controlled Trial Protocol. JMIR Res Protoc (2014) 0.85
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. Arthritis Res Ther (2005) 0.85
1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6). Am J Physiol Endocrinol Metab (2004) 0.85
Depression and mortality in the visually-impaired, community-dwelling, elderly population of Quebec. Acta Ophthalmol (2007) 0.85
Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: a population-based study. BJU Int (2014) 0.85
Factors associated with persistence of cholinesterase inhibitor treatments in the elderly. Pharmacoepidemiol Drug Saf (2010) 0.84
Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone. Int J Oncol (2003) 0.84
Patterns of antidepressant use in Quebec children and adolescents: trends and predictors. Psychiatry Res (2010) 0.83
Physician-pharmacist collaborative care for dyslipidemia patients: knowledge and skills of community pharmacists. J Contin Educ Health Prof (2009) 0.83
Methodological gaps in the assessment of risk minimization interventions: a systematic review. Pharmacoepidemiol Drug Saf (2014) 0.83
Effect of fetal gender on maternal asthma exacerbations in pregnant asthmatic women. Respir Med (2008) 0.82
Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population. J Affect Disord (2008) 0.82
Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab (2007) 0.82
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Atypical femoral fractures and bone turnover. N Engl J Med (2011) 0.82
Impact of prescriber nonresponse on patient representativeness. Epidemiology (2008) 0.82
Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Pharmacoepidemiol Drug Saf (2008) 0.82
Association of age-dependent height and bone mineral density decline with increased arterial stiffness and rate of fractures in hypertensive individuals. J Hypertens (2015) 0.82
The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers. Br J Clin Pharmacol (2009) 0.81
Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study. J Clin Densitom (2008) 0.81
Men had a higher risk of recurrent venous thromboembolism than women: a large population study. Gend Med (2012) 0.80
An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. Thromb Haemost (2016) 0.80
Inhaled corticosteroids vs. leukotriene-receptor antagonists and asthma exacerbations in children. Respir Med (2010) 0.80
The association between length of benzodiazepine use and sleep quality in older population. Int J Geriatr Psychiatry (2010) 0.80
Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol (2014) 0.80
NSAID use profiles derived from reimbursement data in France. Therapie (2005) 0.79
Trends and determinants of antiresorptive drug use for osteoporosis among elderly women. Pharmacoepidemiol Drug Saf (2005) 0.79
Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. J Am Geriatr Soc (2009) 0.79
Impact of maternal asthma on perinatal outcomes: a two-stage sampling cohort study. Eur J Epidemiol (2012) 0.79
Primary care practices and determinants of optimal anticoagulation management in a collaborative care model. Am Heart J (2010) 0.79
Continuity of care in the ambulatory treatment of adolescents with asthma. J Adolesc Health (2006) 0.78
Effectiveness of antibiotics for acute sinusitis in real-life medical practice. Br J Clin Pharmacol (2010) 0.78
Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach. Value Health (2011) 0.78